Acquisition agreement for Advanced BiohealingAgreement and Plan of Merger • November 29th, 2022 • Delaware
Contract Type FiledNovember 29th, 2022 JurisdictionShire has agreed to pay $750 million, in cash, for ABH in a transaction that is expected to close late in the second quarter or early in the third quarter of 2011.
Acquisition agreement for Advanced BiohealingAgreement and Plan of Merger • November 29th, 2022 • Delaware
Contract Type FiledNovember 29th, 2022 JurisdictionShire has agreed to pay $750 million, in cash, for ABH in a transaction that is expected to close late in the second quarter or early in the third quarter of 2011.
Acquisition agreement for Advanced BiohealingAgreement and Plan of Merger • November 2nd, 2022 • Delaware
Contract Type FiledNovember 2nd, 2022 JurisdictionShire has agreed to pay $750 million, in cash, for ABH in a transaction that is expected to close late in the second quarter or early in the third quarter of 2011.
AGREEMENT AND PLAN OF MERGER dated as of MAY 17, 2011 by and among SHIRE PHARMACEUTICALS INC. (“Parent”), ABH MERGER SUB INC. (“Merger Sub”), ADVANCED BIOHEALING, INC. (the “Company”), solely for the purposes of Section 2.7 and Articles III, IX and X,...Agreement and Plan of Merger • June 30th, 2011 • Shire PLC • Pharmaceutical preparations • Delaware
Contract Type FiledJune 30th, 2011 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER (this “Agreement ”) is made and entered into as of May 17, 2011 by and among Shire Pharmaceuticals Inc., a Delaware corporation (“Parent”), ABH Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), Advanced BioHealing, Inc., a Delaware corporation (the “Company”), solely for the purposes of Section 2.7 and Articles III, IX and X, Canaan VII L.P., a Delaware limited partnership, as the Equityholders’ Representative, and solely for the purposes of Section 10.17, Shire plc, a public limited company incorporated under the laws of Jersey, Channel Islands (“Buyer Parent”). Parent, Merger Sub, the Company, solely for the purposes of Section 2.7 and Articles III, IX and X, the Equityholders’ Representative, and solely for the purposes of Section 10.17, Buyer Parent are referred to collectively herein as the “Parties.”